Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia

NCT01121042 is registered in ClinicalTrials.gov with Bayside Health as lead sponsor.

NCT NCT01121042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01121042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia
Lead sponsor
Bayside Health
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2010
Completion date
August 31, 2018
Enrollment
85 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective and schizophreniform disorders, schizophrenia